Asthma Unmasked With Tumor Necrosis Factor-α-Blocking Drugs
We report five cases of asthma unmasked by anti-tumor necrosis factor (TNF)-α-blocking drugs. Asthma symptoms appeared within an average of 4 months (range 1-24 months) after starting the anti-TNF-α treatment for inflammatory disease. The patients did not appear to be predisposed to asthma except fo...
Gespeichert in:
| Veröffentlicht in: | Chest 2011-10, Vol.140 (4), p.1068-1071 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1071 |
|---|---|
| container_issue | 4 |
| container_start_page | 1068 |
| container_title | Chest |
| container_volume | 140 |
| creator | Guilleminault, Laurent, MD Carré, Philippe, MD Beau-Salinas, Frédérique, MD Taillé, Camille, MD, PhD Dieudé, Philippe, MD Crestani, Bruno, MD, PhD Diot, Patrice, MD, PhD Marchand-Adam, Sylvain, MD, PhD |
| description | We report five cases of asthma unmasked by anti-tumor necrosis factor (TNF)-α-blocking drugs. Asthma symptoms appeared within an average of 4 months (range 1-24 months) after starting the anti-TNF-α treatment for inflammatory disease. The patients did not appear to be predisposed to asthma except for one patient who had asthma during childhood. Four patients stopped anti-TNF-α-blocking drugs with an improvement of symptoms within 1 to 5 months. In the patient with a history of childhood asthma, respiratory symptoms recurred when another anti-TNF-α therapy was started. Asthma control was achieved with inhaled steroids, allowing anti-TNF-α treatment to continue. The biotherapy was maintained for the fifth patient in association with inhaled steroids. The pathophysiologic mechanisms are unknown but are probably more complex than the T helper 1/T helper 2 imbalance suggested in the literature, and further studies are required. |
| doi_str_mv | 10.1378/chest.10-2350 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_896527978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0012369211605473</els_id><sourcerecordid>896527978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-cdfe51e68d5e180331f1263f0e281c449b8bcb9ffabaa04327414841b0e7e9fc3</originalsourceid><addsrcrecordid>eNpFkc9O3DAQhy3UChbaY69VLhUnU4_txLaEkCiUFgm1h4J6tBzvmDWbP9ROkHisvkifqQm7wGn0k74ZzXxDyAdgRyCU_uxXmIcjYJSLku2QBRgBVJRSvCELxoBTURm-R_ZzvmNTBlPtkj0ORnGh1YIcn-Zh1bripmtdXuOy-B2HVXE9tn0qfqBPfY65uHB-6BP995d-aXq_jt1tcZ7G2_yOvA2uyfh-Ww_IzcXX67Pv9Ornt8uz0yvqhVID9cuAJWCllyWCZkJAAF6JwJBr8FKaWte-NiG42jkmBVcSpJZQM1RoghcH5HAz9z71f8bpXtvG7LFpXIf9mK02VcmVUXoi6YacN88Jg71PsXXp0QKzsy_75GtOs6-J_7idPNYtLl_oZ0ET8GkLuOxdE5LrfMyvnKyg1E_cyYbDycNDxGR9E7s4tazxEfNdP6ZuUmTBZm6Z_TW_Zv4MQMVKqYT4DyOuiGE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>896527978</pqid></control><display><type>article</type><title>Asthma Unmasked With Tumor Necrosis Factor-α-Blocking Drugs</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><source>Alma/SFX Local Collection</source><creator>Guilleminault, Laurent, MD ; Carré, Philippe, MD ; Beau-Salinas, Frédérique, MD ; Taillé, Camille, MD, PhD ; Dieudé, Philippe, MD ; Crestani, Bruno, MD, PhD ; Diot, Patrice, MD, PhD ; Marchand-Adam, Sylvain, MD, PhD</creator><creatorcontrib>Guilleminault, Laurent, MD ; Carré, Philippe, MD ; Beau-Salinas, Frédérique, MD ; Taillé, Camille, MD, PhD ; Dieudé, Philippe, MD ; Crestani, Bruno, MD, PhD ; Diot, Patrice, MD, PhD ; Marchand-Adam, Sylvain, MD, PhD</creatorcontrib><description>We report five cases of asthma unmasked by anti-tumor necrosis factor (TNF)-α-blocking drugs. Asthma symptoms appeared within an average of 4 months (range 1-24 months) after starting the anti-TNF-α treatment for inflammatory disease. The patients did not appear to be predisposed to asthma except for one patient who had asthma during childhood. Four patients stopped anti-TNF-α-blocking drugs with an improvement of symptoms within 1 to 5 months. In the patient with a history of childhood asthma, respiratory symptoms recurred when another anti-TNF-α therapy was started. Asthma control was achieved with inhaled steroids, allowing anti-TNF-α treatment to continue. The biotherapy was maintained for the fifth patient in association with inhaled steroids. The pathophysiologic mechanisms are unknown but are probably more complex than the T helper 1/T helper 2 imbalance suggested in the literature, and further studies are required.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.10-2350</identifier><identifier>PMID: 21972387</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: American College of Chest Physicians</publisher><subject>Adalimumab ; Administration, Inhalation ; Adult ; Aged ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma - chemically induced ; Asthma - diagnosis ; Asthma - drug therapy ; Biological and medical sciences ; Cardiology. Vascular system ; Chronic obstructive pulmonary disease, asthma ; Female ; Humans ; Infliximab ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Pulmonary/Respiratory ; Rheumatic Diseases - drug therapy ; Steroids - administration & dosage ; Steroids - therapeutic use ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Chest, 2011-10, Vol.140 (4), p.1068-1071</ispartof><rights>The American College of Chest Physicians</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-cdfe51e68d5e180331f1263f0e281c449b8bcb9ffabaa04327414841b0e7e9fc3</citedby><cites>FETCH-LOGICAL-c377t-cdfe51e68d5e180331f1263f0e281c449b8bcb9ffabaa04327414841b0e7e9fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24615887$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21972387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guilleminault, Laurent, MD</creatorcontrib><creatorcontrib>Carré, Philippe, MD</creatorcontrib><creatorcontrib>Beau-Salinas, Frédérique, MD</creatorcontrib><creatorcontrib>Taillé, Camille, MD, PhD</creatorcontrib><creatorcontrib>Dieudé, Philippe, MD</creatorcontrib><creatorcontrib>Crestani, Bruno, MD, PhD</creatorcontrib><creatorcontrib>Diot, Patrice, MD, PhD</creatorcontrib><creatorcontrib>Marchand-Adam, Sylvain, MD, PhD</creatorcontrib><title>Asthma Unmasked With Tumor Necrosis Factor-α-Blocking Drugs</title><title>Chest</title><addtitle>Chest</addtitle><description>We report five cases of asthma unmasked by anti-tumor necrosis factor (TNF)-α-blocking drugs. Asthma symptoms appeared within an average of 4 months (range 1-24 months) after starting the anti-TNF-α treatment for inflammatory disease. The patients did not appear to be predisposed to asthma except for one patient who had asthma during childhood. Four patients stopped anti-TNF-α-blocking drugs with an improvement of symptoms within 1 to 5 months. In the patient with a history of childhood asthma, respiratory symptoms recurred when another anti-TNF-α therapy was started. Asthma control was achieved with inhaled steroids, allowing anti-TNF-α treatment to continue. The biotherapy was maintained for the fifth patient in association with inhaled steroids. The pathophysiologic mechanisms are unknown but are probably more complex than the T helper 1/T helper 2 imbalance suggested in the literature, and further studies are required.</description><subject>Adalimumab</subject><subject>Administration, Inhalation</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma - chemically induced</subject><subject>Asthma - diagnosis</subject><subject>Asthma - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Female</subject><subject>Humans</subject><subject>Infliximab</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Pulmonary/Respiratory</subject><subject>Rheumatic Diseases - drug therapy</subject><subject>Steroids - administration & dosage</subject><subject>Steroids - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc9O3DAQhy3UChbaY69VLhUnU4_txLaEkCiUFgm1h4J6tBzvmDWbP9ROkHisvkifqQm7wGn0k74ZzXxDyAdgRyCU_uxXmIcjYJSLku2QBRgBVJRSvCELxoBTURm-R_ZzvmNTBlPtkj0ORnGh1YIcn-Zh1bripmtdXuOy-B2HVXE9tn0qfqBPfY65uHB-6BP995d-aXq_jt1tcZ7G2_yOvA2uyfh-Ww_IzcXX67Pv9Ornt8uz0yvqhVID9cuAJWCllyWCZkJAAF6JwJBr8FKaWte-NiG42jkmBVcSpJZQM1RoghcH5HAz9z71f8bpXtvG7LFpXIf9mK02VcmVUXoi6YacN88Jg71PsXXp0QKzsy_75GtOs6-J_7idPNYtLl_oZ0ET8GkLuOxdE5LrfMyvnKyg1E_cyYbDycNDxGR9E7s4tazxEfNdP6ZuUmTBZm6Z_TW_Zv4MQMVKqYT4DyOuiGE</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Guilleminault, Laurent, MD</creator><creator>Carré, Philippe, MD</creator><creator>Beau-Salinas, Frédérique, MD</creator><creator>Taillé, Camille, MD, PhD</creator><creator>Dieudé, Philippe, MD</creator><creator>Crestani, Bruno, MD, PhD</creator><creator>Diot, Patrice, MD, PhD</creator><creator>Marchand-Adam, Sylvain, MD, PhD</creator><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111001</creationdate><title>Asthma Unmasked With Tumor Necrosis Factor-α-Blocking Drugs</title><author>Guilleminault, Laurent, MD ; Carré, Philippe, MD ; Beau-Salinas, Frédérique, MD ; Taillé, Camille, MD, PhD ; Dieudé, Philippe, MD ; Crestani, Bruno, MD, PhD ; Diot, Patrice, MD, PhD ; Marchand-Adam, Sylvain, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-cdfe51e68d5e180331f1263f0e281c449b8bcb9ffabaa04327414841b0e7e9fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adalimumab</topic><topic>Administration, Inhalation</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma - chemically induced</topic><topic>Asthma - diagnosis</topic><topic>Asthma - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Female</topic><topic>Humans</topic><topic>Infliximab</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Pulmonary/Respiratory</topic><topic>Rheumatic Diseases - drug therapy</topic><topic>Steroids - administration & dosage</topic><topic>Steroids - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guilleminault, Laurent, MD</creatorcontrib><creatorcontrib>Carré, Philippe, MD</creatorcontrib><creatorcontrib>Beau-Salinas, Frédérique, MD</creatorcontrib><creatorcontrib>Taillé, Camille, MD, PhD</creatorcontrib><creatorcontrib>Dieudé, Philippe, MD</creatorcontrib><creatorcontrib>Crestani, Bruno, MD, PhD</creatorcontrib><creatorcontrib>Diot, Patrice, MD, PhD</creatorcontrib><creatorcontrib>Marchand-Adam, Sylvain, MD, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guilleminault, Laurent, MD</au><au>Carré, Philippe, MD</au><au>Beau-Salinas, Frédérique, MD</au><au>Taillé, Camille, MD, PhD</au><au>Dieudé, Philippe, MD</au><au>Crestani, Bruno, MD, PhD</au><au>Diot, Patrice, MD, PhD</au><au>Marchand-Adam, Sylvain, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asthma Unmasked With Tumor Necrosis Factor-α-Blocking Drugs</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>140</volume><issue>4</issue><spage>1068</spage><epage>1071</epage><pages>1068-1071</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>We report five cases of asthma unmasked by anti-tumor necrosis factor (TNF)-α-blocking drugs. Asthma symptoms appeared within an average of 4 months (range 1-24 months) after starting the anti-TNF-α treatment for inflammatory disease. The patients did not appear to be predisposed to asthma except for one patient who had asthma during childhood. Four patients stopped anti-TNF-α-blocking drugs with an improvement of symptoms within 1 to 5 months. In the patient with a history of childhood asthma, respiratory symptoms recurred when another anti-TNF-α therapy was started. Asthma control was achieved with inhaled steroids, allowing anti-TNF-α treatment to continue. The biotherapy was maintained for the fifth patient in association with inhaled steroids. The pathophysiologic mechanisms are unknown but are probably more complex than the T helper 1/T helper 2 imbalance suggested in the literature, and further studies are required.</abstract><cop>Northbrook, IL</cop><pub>American College of Chest Physicians</pub><pmid>21972387</pmid><doi>10.1378/chest.10-2350</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3692 |
| ispartof | Chest, 2011-10, Vol.140 (4), p.1068-1071 |
| issn | 0012-3692 1931-3543 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_896527978 |
| source | MEDLINE; Journals@Ovid Ovid Autoload; Alma/SFX Local Collection |
| subjects | Adalimumab Administration, Inhalation Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Asthma - chemically induced Asthma - diagnosis Asthma - drug therapy Biological and medical sciences Cardiology. Vascular system Chronic obstructive pulmonary disease, asthma Female Humans Infliximab Male Medical sciences Middle Aged Pneumology Pulmonary/Respiratory Rheumatic Diseases - drug therapy Steroids - administration & dosage Steroids - therapeutic use Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Asthma Unmasked With Tumor Necrosis Factor-α-Blocking Drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T09%3A19%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asthma%20Unmasked%20With%20Tumor%20Necrosis%20Factor-%CE%B1-Blocking%20Drugs&rft.jtitle=Chest&rft.au=Guilleminault,%20Laurent,%20MD&rft.date=2011-10-01&rft.volume=140&rft.issue=4&rft.spage=1068&rft.epage=1071&rft.pages=1068-1071&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.10-2350&rft_dat=%3Cproquest_cross%3E896527978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=896527978&rft_id=info:pmid/21972387&rft_els_id=1_s2_0_S0012369211605473&rfr_iscdi=true |